SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference

DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, Florida on Wednesday, December 3rd at 4:00 pm Eastern Standard Time.

Interested investors and guests of SeaStar Medical are welcome to attend the conference. Please register here using the code ICUNOBLECON for the SeaStar Medical participation rate.

A replay of the presentation will be available on Thursday, December 4th after 4:00 pm Eastern Standard Time on the Company's website and can be accessed here. The replay will be available for up to 30 days following its posting.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The QUELIMMUNE (SCD-PED) therapy is SeaStar Medical’s first commercial product based on its patented Selective Cytopheretic Device (SCD) technology. The QUELIMMUNE (SCD-PED) therapy was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
SeaStar Investor Relations:
[email protected]

You May Also Be Interested In

• Dimensional Fund Advisors Ltd. : Form 8.3 - Consortium comprising LondonMetric Property plc and Schroder Real Estate Investment Trust Limited
• Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
• Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics